Doc's Attys Duel Over Fee Split In $785M Pfizer FCA Deal
Three firms that represented a whistleblower in a False Claims Act suit against a Pfizer subsidiary on Monday set the stage for an upcoming civil trial over fees with briefs disputing...To view the full article, register now.
Already a subscriber? Click here to view full article